Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

m those
presented. There can be no assurance that any other therapeutic entities will enter clinical trials, that clinical trial results will be predictive for
future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing
approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the
background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forwardlooking
statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or
purchase any securities of Cytos Biotechnology AG.



For further information please contact:
Cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schlieren
Claudine Blaser, PhD
Director Corporate Communications
phone: +41 44 733 47 20
e-Mail: claudine.blaser@cytos.com
Website: www.cytos.com
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe , ... , today announced that it now offers the revolutionary ... CPAPs are the first sleep apnea therapy devices with ... and easy to track and share real-time data on ... of their CPAP therapy.  In addition, the internal modem ...
(Date:9/30/2014)... The Chinese wound care market is in ... the incidence of lifestyle diseases, coupled with the increase ... better quality of wound care products provide the impetus ... public health insurance schemes and increased reimbursement rate for ... the findings of primary and secondary researches, this research ...
(Date:9/30/2014)... BRUNSWICK, N.J., Sept. 30, 2014 The ... Kessler Foundation and New Jersey Health Foundation (NJHF) ... and patient care programs has been announced by ... officer of Kessler Foundation and James M. ... "The experience of New Jersey Health ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4China Wound Care Market 2China Wound Care Market 3Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI.OB News), ... for the sale of Gastrodia valued at 67.5 Million ... are with Chongqing Valley Pharm Corp and Sichuan Zhiyuanguanghe ... of 550 tons of Gastrodia from January 1, 2012 to December ...
... Accuray Incorporated (Nasdaq: ARAY ), the ... study demonstrating the benefits of the CyberKnife® Robotic ... the treatment of central lung tumors using gantry based ... a great deal of accuracy to avoid risks of ...
Cached Medicine Technology:China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 3Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 2Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 3Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 4
(Date:9/30/2014)... partnership funded by the Department of Defense (DoD) ... better-run clinical trials and may lead to the ... condition affecting not only athletes and soldiers, but ... youngsters to elders. , Under the partnership, ... million, five-year award from the DoD, the research ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacy” (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Life Length ... provides CHL access to Life Length’s proprietary Telomere Analysis ... and comprehensive telomere test on the market today, and ... the percentage of short telomeres, providing the most critical ... Chairman of the Department of Cell Biology at The ...
(Date:9/30/2014)... 2014 Market Research Report on ... professional and in-depth market survey on Global and ... basic information of Cialis including its classification, application ... and China’s top manufacturers of Cialis listing their ... etc. , The report further analyzes quantitatively 2009-2014 ...
(Date:9/30/2014)... 30, 2014 Catalent Pharma Solutions ... delivery technologies and development solutions for drugs, biologics ... agenda for the 25th Annual CPhI Worldwide Exhibition ... 6th to 9th. , Catalent is showcasing a ... during the show, including its facilities in China ...
Breaking Medicine News(10 mins):Health News:US aims for traumatic brain injury clinical trial success 2Health News:US aims for traumatic brain injury clinical trial success 3Health News:US aims for traumatic brain injury clinical trial success 4Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 2Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3
... HIV case in Libya involving five Bulgarian nurses and a ... that they were tortured brutally to give false testimonies. ... when they were accused of starting an HIV epidemic in ... the infections have begun much before the arrival of these ...
... the better your heart health. But a man’s heart ... relationships among cholesterol levels,// psychological function, and neurologic disorders ... Harvard Men’s Health Watch. ,There are ... disease. Vascular dementia results when blood vessel damage deprives ...
... launched ‘The HumaPen Memoir’ the world's first digital insulin pen ... simplifies the management of diabetic patients who require timely insulin ... designed to meet the needs of people with diabetes who ... ,The unique pen memory device can help the patient to ...
... select patients for further testing may increase detection of ... colorectal cancer at a young age, //researchers report in ... National Cancer Institute. ,Lynch syndrome, also known ... mutations in DNA mismatch repair genes, the genes that ...
... key signaling protein in the brain during infancy could ... //According to findings published today in the journal Nature, ... serotonin just after birth exhibit abnormal anxiety as adults. ... mice genetically engineered to lack the receptor for serotonin, ...
... cases of dengue fever were reported across Paraguay in the ... new //cases a day last week, Paraguay's health authorities said ... has not yet declared the epidemic to be a health ... ,Dengue fever is a viral infection spread by the ...
Cached Medicine News:Health News:Mouse Study Suggests Anxiety Disorders Take Root in Infancy 2
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Toothed pituitary rongeur....
Bateman pituitary forceps, round cup, 5 mm bite, fenestrated crocodile jaws, 150 mm effective....
Bayonet Kerrison Rongeur, ceramic ejector, 9.5 length 40 Fwd, 6.5 working length 165 mm....
Medicine Products: